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Abstract
Background:  Peritoneal  disseminated  disease,  regardless  of  its  origin,  should  currently  be  con-
sidered a  locoregional  disease  stage,  and  thus  a  candidate  for  an  intention  to  treat  therapeutic
option with  debulking  surgery  and  hyperthermic  intraperitoneal  chemotherapy.
Objective:  To  determine  whether  or  not  the  collagen  sponge  with  ﬁbrinogen  5.5  mg  and  throm-
bin 2  IU,  applied  as  a  tissue  sealant  and  gastrointestinal  reinforcement  sutures,  contributes  to
the reduction  of  anastomotic  leak.
Material  and  methods:  Quasi-experimental,  comparative,  prospective,  case/control  study  con-
ducted on  patients  with  peritoneal  carcinomatosis  of  colorectal  origin,  operated  on  in  our
Peritoneal  Cancer  Surgery  Unit  from  2011  to  April  2014.  The  study  included  73  patients,  43
(59%) men  and  30  (41%)  women  with  peritoneal  carcinomatosis  of  colorectal  origin,  candidates
for debulking  surgery  and  hyperthermic  intraperitoneal  chemotherapy.  Gastrointestinal  anas-
tomoses were  performed  on  49  (67%)  patients.  These  patients  were  randomised  into  2  groups:
A control  (27)  and  B  hypothesis  (22)  reinforced  with  sponge  suture.
Results:  The  total  number  of  anastomoses  performed  was  49  (mean:  1.9),  with  27  in  the
control group  A  (mean:  1.88)  and  22  in  B  (mean:  2.16).  The  debulkings  achieved  were:  com-
plete debulking  0.38  (77.5%),  complete  debulking  1:  7  (14.8%),  and  4  (8.1%)  did  not  undergo
 Please cite this article as: Torres-Melero J, Motos-Micó JJ, Lorenzo-Lin˜án M, Morales-González Á, Rosado-Cobián R. Aplicación de
ellante tisular como refuerzo de las anastomosis digestivas realizadas en pacientes con carcinomatosis peritoneal tratados con inten-
ión curativa mediante procedimiento quirúrgico de citorreducción y quimioterapia intraperitoneal intraoperatoria hipertérmica. Cir Cir.
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hyperthermic  intraperitoneal  chemotherapy  due  to  complete  debulking  >  2.  Intestinal  ﬁstula:  3
cases (6.1%)  in  A  group  vs  0  in  B.
Conclusions:  In  our  series,  the  use  of  a  ﬁbrinogen  and  thrombin  sponge  has  contributed  to  a
signiﬁcant  reduction  in  the  risk  of  gastrointestinal  ﬁstulas  in  high  risk  oncology  patients.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Published  by  Masson  Doyma  México  S.A.  This  is
an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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con  ﬁbrinógeno
Aplicación  de  sellante  tisular  como  refuerzo  de  las  anastomosis  digestivas  realizadas
en  pacientes  con  carcinomatosis  peritoneal  tratados  con  intención  curativa  mediante
procedimiento  quirúrgico  de  citorreducción  y  quimioterapia  intraperitoneal
intraoperatoria  hipertérmica
Resumen
Antecedentes:  La  enfermedad  peritoneal  diseminada  debe  considerarse  como  un  estadio  loco-
rregional de  la  enfermedad,  y  por  tanto,  candidata  a  una  opción  terapéutica  con  intención
curativa  mediante  cirugía  citorreductora  y  quimioterapia  intraperitoneal  hipertérmica  perio-
peratoria.
Objetivo:  Comprobar  si  la  esponja  de  colágeno  con  ﬁbrinógeno  5.5  mg  y  trombina  2  UI,  aplicada
como sellante  tisular,  contribuye  a  la  reducción  del  número  de  dehiscencia  anastomóticas.
Material  y  métodos: Estudio  cuasi-experimental,  comparativo,  prospectivo,  caso  y  controles  en
pacientes  con  carcinomatosis  peritoneal  de  origen  colorrectal,  intervenidos  en  nuestra  Unidad
de Cirugía  Oncológica  Peritoneal  desde  2011  hasta  abril  de  2014.  Nuestra  serie  consta  de  73
pacientes, 43  (59%)  hombres  y  30  (41%)  mujeres,  diagnosticados  de  cáncer  de  origen  colorrectal
y candidatos  a  cirugía  citorreductora  y  quimioterapia  intraperitoneal  hipertérmica  perioperato-
ria. En  49  pacientes  (67%)  se  realizaron  anastomosis  digestivas;  dichos  pacientes  se  aleatorizaron
en 2  grupos:  A  control  (27),  y  B  hipótesis  (22)  con  sutura  reforzada  con  esponja.
Resultados:  El  número  total  de  anastomosis  fueron  49  (x:  1.9),  27  en  el  grupo  A  (x:  1.88)  y  22
en B  (x:  2.16).  Las  citorreducciones  alcanzadas  fueron:  citorreducción  completa  0:  38  (77.5%),
citorreducción  completa  1:  7  (14.8%),  y  en  4  (8.1%)  no  se  realizó  quimioterapia  intraperitoneal
hipertérmica  perioperatoria  por  citorreducción  completa  >  2.  Fístula  intestinal:  3  casos  (6.1%)
en el  grupo  A  (sin  esponja  medicamentosa)  frente  a  0  en  el  grupo  B.
Conclusión:  El  empleo  en  nuestra  serie  de  la  esponja  de  ﬁbrinógeno  y  trombina  ha  contribuido
a una  reducción  signiﬁcativa  del  riesgo  de  fístulas  digestivas,  en  pacientes  oncológicos  de  alto
riesgo.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Publicado  por  Masson  Doyma  México  S.A.  Este  es
un artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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trointestinal  anastomotic  leakage  in  animal  models.  TheBackground
At  present,  peritoneal  disseminated  disease  or  peritoneal
carcinomatosis  should  be  considered  a  locoregional  dis-
ease  stage  of  the  disease  regardless  of  its  origin  and  thus
a  candidate  for  an  intention-to-treat  therapeutic  option
with  debulking  surgery  and  hyperthermic  intraperitoneal
chemotherapy.
The  high  rate  of  morbidity  with  this  technique  (30--65%)
can  be  signiﬁcantly  reduced  by  maximising  the  selection  of
candidates  for  surgery  by  referrals  to  specialist  units  with
multidisciplinary  cohesive  teams,  and  by  the  use  of  a  reﬁned
surgical  technique  to  reduce  the  amount  of  complications
which  include  intestinal  ﬁstulae,  amongst  others.1 Periop-
erative  anastomotic  dehiscence  after  debulking  surgery  and
hyperthermic  intraperitoneal  chemotherapy  varies  between
5%  and  12%.  Many  procedures  have  been  developed  to  reduce
p
m
whe  risk  of  anastomotic  leakage,  including  the  use  of  mate-
ials  to  reinforce  suture  lines.2
The  medicated  sponge  contains  (per  cm2)  human  ﬁbrin-
gen  5.5  mg  and  human  thrombin  2  IU,  and  is  indicated  in
dults  as  supportive  treatment  in  several  surgical  proce-
ures  to  improve  haemostasis,  promote  tissue  sealing  and
s  reinforcement  for  sutures  in  vascular  surgery.
The  objective  of  the  study  was  to  check  whether  the
ollagen  sponge  with  5.5  mg  of  ﬁbrinogen  and  2  IU  of
hrombin  applied  as  a  tissue  sealant  and  as  gastrointesti-
al  reinforcement  sutures  contributes  or  not  to  a reduced
umber  of  anastomotic  leakages.  This  compound  has  been
emonstrated  as  effective  in  reducing  the  rate  of  gas-resence  of  ﬁbrinogen  and  thrombin  around  the  suture  pro-
otes  sealing  of  the  suture  and  forms  biological  bridges,
hich  promote  healing.  The  material  disappears  through  the
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ndogenous  metabolic  pathways  of  ﬁbrin  and  this  avoids  the
omplications  associated  with  other  non-degradable  pros-
hesis  materials.
aterial and methods
e  designed  this  quasi-experimental,  comparative,
rospective  case  and  control  study  in  patients  with  gas-
rointestinal  peritoneal  carcinomatosis  of  colorectal  origin
colorectal  carcinoma),  operated  in  our  Surgical  Peritoneal
ncology  Unit;  between  1  January  of  2011  and  1 January
014  where  we  used  the  medicated  sponge  in  patients
ith  gastrointestinal  anastomoses.  Our  series  comprised  73
atients,  43  (59%)  men  and  30  women  (41%),  all  of  whom
ad  been  diagnosed  with  peritoneal  carcinomatosis  and
ere  candidates  for  potentially  curative  surgical  treatment
sing  debulking  techniques  and  perioperative  hyperthermic
ntraperitoneal  chemotherapy.  Gastrointestinal  anasto-
oses  were  performed  on  49  (67%)  of  these  patients,  28
en  and  21  women,  with  peritoneal  carcinomatosis  of
olorectal  origin.  These  patients  were  divided  randomly
nto  2  groups:  Group  A/control  (n  =  27):  mean  age  61.5
range:  39--72).  The  medicated  sponge  was  not  used  in  this
roup.
Group  B/cases  (n  =  22):  mean  age  56.2  (range:  35--69),
he  anastomosis  line  was  reinforced  with  the  medicated
ponge.
The  procedures  used  in  the  patients  (cases)  and  in  the
ontrols  were  carried  out  after  informed  consent  had  been
iven  and  our  centre’s  established  protocols  were  followed.
All  the  sutures  were  mechanical  and  always  placed  by  the
 same  surgeons.  The  sponge  was  placed  covering  the  entire
c
p
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igure  1  Reinforcement  of  an  anastomosis  using  a  medicated  sp
ight hemicolectomy  in  a  patient  with  peritoneal  carcinomatosis  of
ith an  electrosurgical  unit  of  the  jejunum  and  transverse  colon.  B.
. Final  result  of  mechanical  jejunocolic  latero-lateral  anastomosis.  J.  Torres-Melero  et  al.
nastomosis,  overlapping  at  least  0.5--1  cm  at  each  side  of
he  suture  line  and  exercising  slight  pressure  on  it  (Fig.  1).
he  size  of  the  sponge  used  was  9.5  cm  ×  4.8  cm.
Most  of  the  anastomoses  were  covered  with  a  single
heet,  if  2  or  more  were  required,  this  was  recorded  in  the
atient’s  clinical  history.  Neither  group  presented  signiﬁcant
opulational  differences  (Table  1).
Inclusion  criteria:  patients  diagnosed  with  peritoneal
arcinomatosis  of  colorectal  origin  and  candidates  for  poten-
ially  curative  surgical  treatment  using  debulking  techniques
nd  perioperative  intraperitoneal  hyperthermic  chemother-
py.
Exclusion  criteria:  patients  diagnosed  with  periton-
al  carcinomatosis  which  was  not  colorectal  in  origin.
atients  who  had  undergone  a  different  operation  (perit-
neal  normothermic  chemotherapy).  No  patients  were  lost
o  follow-up.
The  study  variables  were  gender,  age,  pathological
natomy,  histological  grade,  clinical  signs,  peritoneal
arcinomatosis  index,  peritoneal  carcinomatosis  index
intraoperative)  and  degree  of  debulking.
All  the  patients  included  in  this  study  fulﬁlled  strict  inclu-
ion  criteria  for  surgical  treatment  using  debulking  surgery
nd  intraperitoneal  perioperative  hyperthermic  chemother-
py  and  were  informed,  orally  and  in  writing,  of  their
articipation  in  the  study.  The  patient’s  signature  was
equired  for  their  inclusion  and  that  of  a  close  relative.  In
ll  cases,  we  complied  with  current  legislation  including  the
urrent  Data  Protection  Act.
According  to  the  pathological  anatomy  of  the  surgical
iece,  the  tumours  were  staged  as:  IIIA  (one),  IIIB  (11),  IIIC
17)  and  IVB  (20).  G1:  7  (14%),  G2:  30  (61%)  and  G3:12  (24%).
onge.  Mechanical  jejunocolic  latero-lateral  anastomosis  after
 colorectal  origin.  A.  Preparation  of  the  anastomosis:  incision
 Insertion  of  GIA  75  mm  through  both  incisions  for  anastomosis.
D.  Placing  the  medicated  sponge  on  the  intestinal  anastomosis.
Use  of  ﬁbrin  sealant  patch  in  digestive  anastomosis  
Table  1  Patient  characteristics.
Group  A
n =  27
Group  B
n =  22
p
Gender
Male  15  13  0.7893
Female  12  9  0.5371
Age 61.5  (±  0.12)  56.2  (±  0.12)
Pathological  anatomy
IIIA 0  5  0.0114
IIIB 5  6  1
IIIC 10  7  0.4927
IV 9  11  0.7518
Histological  grade
G1  3  4  1
G2 16  14  0.7963
G3 7  5  0.6831
Mucinous  4  3  1
Clinical  symptoms
Asymptomatic  2  3  1
Moderate  20  23  0.662
Severe 1  0  1
Peritoneal  carcinomatosis  index
< 10  8  10  0.7389
10--20 14  15  1
< 20  1  1  0.3173
Peritoneal  carcinomatosis  index  (intraoperative)
< 10  8  10  0.7389
10--20 15  15  0.7963
> 20  1  1  0.3173
Debulking  grade
CC0  18  20  0.8581
CC1 3  4  1
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CC2--CC3.  There  was  anastomotic  dehiscence  and  intestinalCC2 3  1  0.4795
Mucinous  7  (15%).  According  to  the  symptoms  presented:  5
(10%)  asymptomatic,  43  (88%)  with  moderate  symptoms  and
one  (2%)  with  major  symptoms.  The  radiological  peritoneal
carcinomatosis  index  was  ≤  10:  18  cases  (36%),  between
ﬁ
o
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Table  2  Peritoneal  Surface  Disease  Severity  Score  (PSDSS).
Symptom-free:  0  Peritoneal  carcinomatosis  index  <  10  (lo
Moderate symptoms:  1  Peritoneal  carcinomatosis  index  =  10--2
(medium):  3
Severe symptoms:  6  Peritoneal  carcinomatosis  index  >  20  (h
Sum PSDSS  (Peritoneal  Surface  Disease  Seve
2--3 Severity  I
4--7 Severity  II
8--10 Severity  III
> 10  Severity  IV105
0  and  20:  29  (59%)  and  2  with  a peritoneal  carcinomatosis
ndex  ≥  20.  Thirty-seven  (75.5%)  patients  received  adjuvant
hemotherapy  stages  IIIC  and  IVB.
After  the  various  surgical  techniques  in  peritonectomy,
lectrofulguration  and  visceral  resection  had  been  per-
ormed,  only  the  patients  who  achieved  CC0--CC1  underwent
erioperative  intraperitoneal  hyperthermic  chemotherapy
sing  the  Sugabaker  protocol  with  mytomicin  +  doxorubicin
t  42 ◦C  for  90  min.  The  peritoneal  carcinomatosis  index  was
 10  in  15  cases  (30%),  between  10  and  20  in  32  (65%)  and  ≥
0  in  2  (5%).  They  were  all  staged  preoperatively  according
o  the  Peritoneal  Surface  Disease  Severity  Score  (Table  2).
After  a  mean  follow-up  of  24  months,  the  patients
ere  classiﬁed  according  to  their  clinical  situation  as:
isease-free,  alive  with  disease,  deceased  due  to  and
ithout  disease.  In  both  groups,  the  intestinal  tract
as  reconstructed  after  administration  of  intraoperative
ntraperitoneal  hyperthermic  chemotherapy.  All  the  sutures
ere  mechanical  and  always  placed  by  the  same  2  surgeons.
n  group  A  (control)  the  anastomoses  were  not  reinforced
ith  medicated  sponge,  and  in  group  B  they  were,  following
he  manufacturer’s  standards.
tatistical  study
earson’s  2 test  was  used  for  the  baseline  comparisons  of
he  patients’  characteristics  or  the  Fisher  test  as  appropri-
te.  The  differences  in  the  incidence  of  anastomotic  ﬁstulae
ere  measured  using  Fisher’s  bilateral  exact  test.  For  all  the
nalyses  the  level  of  statistical  signiﬁcance  was  set  at  5%,
alue  ˛  =  0.05.
esults
here  were  a  total  of  19  anastomoses  (x˙:  19),  27  in  Group
 (49.4%, x˙:  1.88)  and  22  in  group  B  (54.7%, x˙:  2.16).  The
ebulkings  achieved  were:  CC0  in  38  patients  (77.5%),  CC1
n  7  (14.8%),  and  in  4  (8.1%)  perioperative  intraperitoneal
yperthermic  chemotherapy  was  not  undertaken  due  tostula  in  3  cases  (6.1%);  2  of  them  in  the  CC0--CC1  group  and
ne  in  the  CC2--CC3  group.  The  3  in  group  A/control  (without
edicated  sponge)  compared  to  none  in  group  B/hypothesis.
w):  1  Histological  grade  (G1):  1
Histological  grade  (G2)  with  negative  lymph
nodes,  with  no  lymphatic  or  vascular
invasion:  1
0 Histological  grade  (G2)  with  positive  lymph
nodes,  lymphatic  or  vascular  invasion:  3
igh):  7  Histological  grade  (G3):  9
Histological  grade  (signet  ring):  9
rity  Score)
106  
Table  3  Results.
Results  Group  A  Group  B  p
No.  of  anastomoses  49  27  22  0.5697
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(Rate of  anastomosis  1.88  2.16
No. of  dehiscences  (3/49)  3/47  0/22  0.2066
wo  of  them  required  reoperation  (stomas)  with  signiﬁcantly
ncreased  postoperative  time.  The  mean  admission  time  in
ur  series  for  uncomplicated  patients  was  14  days  com-
are  to  a  mean  of  26  days  in  the  cases  complicated  with
ntestinal  ﬁstula.  Two  patients  (4.1%)  presented  haemoperi-
oneum,  one  per  group,  and  both  were  reoperated.  The
verall  morbidity  rate  was:  31.7%,  grade  I--II  (21.5%),  grade
II--IV  (10.2%)  (Table  3).
iscussion
er  cm2 the  medicated  sponge  contains  5.5  mg  human  ﬁbro-
en  and  2  IU  human  thrombin  in  the  form  of  a  dry  layer  on  the
urface  of  a  collagen  matrix.  When  in  contact  with  physio-
ogical  ﬂuids  (blood,  lymph  or  saline  solution,  for  example)
he  components  of  this  layer  dissolve  and  partially  spread
ver  the  surface  of  the  wound.  Then  a  reaction  of  the  ﬁbrin-
gen  and  the  thrombin  is  produced  which  starts  the  last
tage  of  physiological  blood  coagulation.  Fibrinogen  con-
erts  into  ﬁbrin  monomers  that  polymerise  spontaneously
o  form  a  ﬁbrin  coagulate,  which  keeps  the  collagen  matrix
rmly  adhered  to  the  wound  surface.  The  ﬁbrin  cleaves  in
ross-links  due  to  endogen  factor  XIII,  creating  a  ﬁrm  and
echanically  stable  net  with  good  adhesive  properties,  and
herefore  at  the  same  time  serves  as  a  sealant.
The  medicated  sponge  is  indicated  for  epilesional  use
nly.  Intravascular  administration  is  contraincidated.  As
 consequence,  pharmacokinetic  studies  have  not  been
erformed  on  humans.  Fibrin/haemostatic  sealants  that
etabolise  in  the  same  way  as  endogenous  ﬁbrin  by  ﬁbrino-
ysis  and  phagocytosis.  In  studies  on  animals,  the  medicated
ponge  biodegrades  after  administration  on  the  wound
urface,  and  little  remains  after  13  weeks.  Complete  degra-
ation  of  the  medicated  sponge  was  observed  in  some
nimals  12  months  after  administration  on  a  wound  in  the
iver,  while  in  others  small  remains  were  seen.  Degrada-
ion  was  associated  with  the  inﬁltration  of  granulocytes
nd  the  formation  of  resorbable  granulation  tissue  that
ncapsulated  the  remains  of  the  gradual  degradation  of  the
edicated  sponge.  No  evidence  of  local  intolerance  was
bserved  in  the  studies  on  animals.  From  experience  gained
n  humans,  a  few  isolated  cases  have  been  found  where
emains  found  incidentally  did  not  cause  functional  damage.
The  morbidity  of  multidisciplinary  treatment  in  per-
toneal  carcinomatosis  is  signiﬁcant.1--3 Speciﬁc  surgical
orbidity  is  30%  and  essentially  corresponds  to  gastrointesti-
al  suture  dehiscences,  perforations  and  intestinal  ﬁstulae,
ollections  or  intrabdominal  abscesses  and  postoperative
leeding,  requiring  10%  of  patients  to  be  reoperated  once
r  several  times.4
The  incidence  of  dehiscence  or  anastomotic  leakage
s  a  postoperative  complication  after  colonic  surgery
s  estimated  at  around  2--5%,  associated  with  increased
s
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orbimortality.  Determining  the  exact  cause  of  a  ﬁstula
s  difﬁcult,  various  factors  are  involved  including,  malnu-
rition,  hypoproteinaemia,  inappropriate  surgical  technique
poor  vascularisation  of  the  intestinal  ends,  anastomosis
nder  tension),  amongst  others.  Whether  or  not  the  colon
hould  be  prepared  prior  to  surgery  is  still  a  matter  of
ebate.  The  major  complications  of  anastomotic  leakage  are
epsis  from  intraperitoneal  abscesses  (50%),  fecaloid  peri-
onitis  (25%),  wall  abscesses  and  wound  infections  (25%),
ith  a  major  impact  on  hospital  stay.1,3--8
Many  surgical  techniques  and  procedures  have  been
eveloped  to  reduce  the  risk  of  anastomotic  leakage,  includ-
ng  the  use  of  materials  to  reinforce  the  suture  line.
hese  include  ﬁbrin  glue,  expanded  polytetraﬂuoroethy-
ene,  bovine  pericardium  patches  polyglycol  and  oxidised
ellulose  patches,  amongst  many  others.  However,  ran-
omised,  controlled  prospective  studies  are  necessary  to
btain  evidence  of  their  efﬁcacy.2
The  sponge  is  indicated  in  adults  as  support  treatment
n  various  surgical  interventions  to  improve  haemostasis,
romote  tissue  sealing  and  to  reinforce  sutures  in  vascular
urgery  when  standard  techniques  have  proved  insufﬁcient.
ts  efﬁcacy  and  safety  have  been  demonstrated  in  vari-
us  types  of  surgery,  for  example  after  liver  resections,9,10
educing  biliary  drainage,  blood  loss  from  the  liver  bed,
nd  consequently  a  reduction  in  hospital  stay.  Chirletti
t  al.11 demonstrated  its  efﬁcacy  in  the  prevention  of
ancreaticojejunal  anastomotic  leakage  after  cephalic  duo-
enopancreatectomy.  Rickenbacher  et  al.2 and  Toro  et  al.12
ublished  reviews  on  the  use  of  the  tissue  sealant  in  abdom-
nal  surgery,  they  reported  no  complications  associated  with
mmunogenicity  or  safety.  Its  efﬁcacy  was  demonstrated
n  reducing  the  number  of  oesophagogastric  and  intesti-
al  anastomotic  leakages  in  various  experimental  models.13
owever,  the  number  of  publications  which  refer  to  its  use
n  preventing  anastomotic  dehiscence  in  colorectal  surgery
s  very  limited.  Parker  et  al.14 observed  fewer  leaks  in  26
atients  who  underwent  anterior  colorectal  resections  in
he  group  of  patients  with  anastomoses  reinforced  using
he  medicated  sponge.  These  results  are  very  similar  to
hose  obtained  by  De  Stefano  et  al.15 in  63  patients,  with
 signiﬁcant  reduction  in  the  number  of  colorectal  anasto-
otic  leakages  in  the  group  treated  using  this  compound.
abino  et  al.16 recently  reported,  in  an  experimental  rat
odel,  the  effect  of  immediate  postoperative  intraperi-
oneal  chemotherapy  on  the  healing  processes  which  take
lace  in  manual  colocolic  anastomoses  in  left  hemicolec-
omies.  It  can  be  observed  how  5-ﬂuorouracil  impedes  these
echanisms,  promoting  anastomotic  dehiscence.  On  the
ther  hand,  fewer  anastomotic  leakages  are  seen  in  the
roup  of  animals  whose  suture  line  had  been  protected  with
he  medicated  sponge.
To  the  best  of  our  knowledge  there  is  no  study  which
efers  to  the  potential  role  in  the  prevention  of  anasto-
otic  leakage  in  patients  with  peritoneal  carcinomatosis,
ho  have  undergone  total  debulking  techniques  and
ntraoperative  intraperitoneal  hyperthermic  chemotherapy
multimodal  treatment).  In  relation  to  the  rates  of  ana-
tomotic  dehiscence,  most  authors1,3,5--8 report  values  of
.5%  associated  with  the  duration  of  the  operation  and  the
xtent  of  the  implant.  Sugarbaker1,17 stresses  that  the  dura-
ion  of  surgery,  the  number  of  peritonectomy  procedures
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and  the  number  of  sutures  are  independent  risk  factors  of
anastomotic  dehiscence.  Glockzin  et  al.4 report  a  strong
relationship  between  the  extent  of  debulking  and  the  devel-
opment  of  postoperative  complications  with  an  8.9%  rate
of  anastomotic  leakage  and  an  intraabdominal  infection
rate  of  11.3%.  Baratti  et  al.6 describe  a  6.9%  rate  of  ana-
stomotic  dehiscence.  In  their  study,  multivariable  logistic
regression  indicates  that  the  duration  of  surgery  (>  540  min)
and  the  peritoneal  carcinomatosis  index  (>  19)  are  indepen-
dent  predictive  factors.  For  their  part,  Bartlett  et  al.18 on
795  patients  operated  due  to  gastrointestinal  and  gynae-
cological  peritoneal  carcinomatosis  using  total  debulking
techniques  and  intraoperative  intraperitoneal  hyperthermic
chemotherapy  observe,  in  their  multivariable  analysis  that
aged  over  60,  albumin  levels  of  below  3  g/dl,  operation
time  (>  500  min)  and  requirements  for  transfusion  are  asso-
ciated  with  an  increase  in  morbimortality.  As  is  logical,  the
number  of  anastomosis  performed  plays  an  important  role
in  the  percentage  of  postoperative  complications.  There
is  no  evidence  that  the  various  perfusion  techniques  or
the  intraperitoneal  hyperthermic  chemotherapy  itself  inﬂu-
ence  postoperative  complications.1,5--8 It  is  evident  that
the  development  of  operative  complications  has  a  negative
impact  on  the  patient’s  cancer  outcome.
In  our  series,  the  rate  of  anastomotic  leakages  was
3  cases,  all  the  group  of  patients  in  whom  the  ﬁbrin-
thrombin  collagen  sponge  was  not  used.  All  the  patients
were  included  because  they  presented  peritoneal  (carcino-
matosis)  of  colorectal  origin:  one  anastomotic  ﬁstula  after
right  hemicolectomy,  one  after  sigmoidectomy  and  pelvic
peritonectomy  after  systemic  neoadjuvant  chemotherapy
for  synchronous  colorectal  peritoneal  carcinomatosis,  and
a  third  leakage  from  a  mechanical  latero-lateral  jejuno-
jejunal  ﬁstula  in  a  patient  with  implants  for  a  left  colon
tumour  (synchronous  peritoneal  carcinomatosis)  and  with
various  implants  in  the  mid  jejunum  which  were  inﬁltrating
the  muscle  layer  and  which  required  resections  of  segments
of  small  intestine.  The  ﬁrst  2  occurred  after  intraopera-
tive  intraperitoneal  hyperthermic  chemotherapy,  whereas
another  occurred  in  a  patient  with  CC2--CC3  (incomplete
debulking),  and  therefore,  not  candidates  for  intraopera-
tive  chemotherapy.  The  mortality  described  varies  between
0%  and  14%,  although  ﬁgures  of  2%-6%  appear  as  the
most  frequent  in  most  of  the  studies.  It  is  3%  in  our
overall  series.  Mortality  is  associated  with  the  origin  of
the  peritoneal  carcinomatosis  (greater  in  peritoneal  pseu-
domyxoma  in  relation  to  a  high  peritoneal  carcinomatosis
index).  Furthermore,  it  has  also  been  associated  with
the  intensity  of  surgical  aggression;  the  number  of  peri-
tonectomy  procedures  performed  reﬂects  this,  and  the
peritoneal  carcinomatosis  index  (more  than  5  anatomical
regions  affected),  the  number  of  gastrointestinal  anasto-
mosis  and  the  volume  of  blood  transfused  preoperatively.
Although  the  mean  mortality  described  with  this  complex
treatment  does  not  exceed  that  referenced  in  major  diges-
tive  surgery,  the  percentage  and  importance  of  morbidity
and  surgical  complications  that  imply  reoperating  very  frail
patients,  mean  that  a  very  careful  selection  of  patients
should  be  made.  The  morbimortality  relates  directly  to  the
experience  of  the  surgical  team.1--3
Although  we  are  aware  that  there  are  too  few  cases
(n  =  49)  in  our  study  for  us  to  extract  concrete  and  signiﬁcant107
onclusions,  the  study  can  serve  to  start  and  incentivise  the
esign  of  further  randomised,  prospective  studies  recruiting
 larger  number  of  patients  in  order  to  clarify  the  role  of  the
edicated  sponge  in  the  prevention  of  intestinal  anastomo-
ic  leakage.
In  conclusion,  in  a  selected  group  of  patients,  we
onsider  that  peritoneal  carcinomatosis  of  gastrointestinal
nd  gynaecological  origin  is  potentially  curable.  The  best
herapeutic  option  is  total  debulking  surgery  and  intraoper-
tive  intraperitoneal  hyperthermic  chemotherapy.  We  must
nsure  that  we  assess  these  patients  in  specialised  units  with
ultidisciplinary  teams.  In  our  series,  the  use  of  the  med-
cated  sponge  to  reinforce  intestinal  anastomoses  proved
afe  and  effective  and  contributed  to  a  reduction  in  the  risk
f  digestive  ﬁstula  in  patients  who,  as  oncology  patients,
re  at  high  risk  of  dehiscence  having  undergone  extensive
nd  prolonged  surgery;  almost  all  of  them  treated  previously
ith  systemic  chemotherapy  and  generally  malnourished.
fter  a  thorough  search  of  the  major  literature  databases,
his  study  is  the  ﬁrst  to  demonstrate  the  preventive  role  in
he  development  of  anastomotic  dehiscence  of  the  applica-
ion  of  the  medicated  sponge  in  patients  with  peritoneal
mplants  treated  surgically  with  curative  intent  by  total
ebulking  surgery  and  intraoperative  intraperitoneal  hyper-
hermic  chemotherapy.
onﬂict of interests
he  authors  have  no  conﬂict  of  interests  to  declare.
eferences
1. Sugarbaker PH. Early intervention for treatment and prevention
of colorectal carcinomatosis. A plan for individual care. Surg
Oncol Clin N Am. 2012;21:689--703.
2. Rickenbacher A, Breitenstein S, Lesurtel M, Frilling A. Efﬁ-
cacy of TachoSil a ﬁbrin-based haemostat in different ﬁelds of
surgery -- a systematic review. Expert Opin Biol Ther. 2009;9:
897--907.
3. Losa F, Barrios P, Salazar R, Torres-Melero J, Benavides M,
Massuti T, et al. Cytoreductive surgery and intraperitoneal
chemotherapy for treatment of peritoneal carcinomatosis from
colorectal origin. Clin Transl Oncol. 2014;16:128--40.
4. Glockzin G, Ghali N, Lang SA, Schlitt HJ, Piso P. Results
of cytoreductive surgery and hyperthermic intraperitoneal
chemotherapy for peritoneal carcinomatosis from colorectal
cancer. J Surg Oncol. 2009;100:306--10.
5. Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of
peritoneal carcinomatosis by cytoreductive surgery and hyper-
thermic intraperitoneal chemotherapy still be regarded as a
highly morbid procedure? A systematic review of morbidity and
mortalitiy. Ann Surg. 2009;249:900--7.
6. Baratti D, Kusamura S, Iusco D, Bonomi S, Grassi A, Virzi S, et al.
Postoperative complications after cytoreductive surgery and
hyperthermic intraperitoneal chemotherapy affect long-term
outcome of patients with peritoneal metastases from colorec-
tal cancer: a two-center study of 101 patients. Dis Col Rectum.
2014;57:858--68.
7. Elias D, Mariani A, Cloutier AS, Blot F, Goéré D, Dumont F, et al.
Modiﬁed selection criteria for complete cytoreductive surgery
plus HIPEC, based on peritoneal cancer index and small bowel
involvement for peritoneal carcinomatosis of colorectal origin.
Eur J Surg Oncol. 2014;40:1467--73.
11
1
1
1
1
1
1
1
108  
8. Esquivel J, Lowy AM, Markman M, Chua T, Pelz J, Baratti D,
et al. The American Society of Peritoneal Surface Malignancies
(ASPSM) multiinstitution evaluation of the Peritoneal Surface
Disease Severity Score (PSDSS) in 1,013 patients with colorec-
tal cancer with peritoneal carcinomatosis. Ann Surg Oncol.
2014;21:4195--201.
9. Bricen˜o J, Naranjo A, Ciria R, Díaz-Nieto R, Sánchez-Hidalgo
JM, Luque A, et al. A prospective study of the efﬁcacy of clini-
cal application of a new carrier-bound ﬁbrin sealant after liver
resection. Arch Surg. 2010;145:482--8.
0. Toti L, Attia M, Manzia TM, Lenci I, Gunson B, Buckels JA,
et al. Reduction in bile leaks following adult split liver trans-
plant using a ﬁbrin-collagen sponge: a pilot study. Dig Liver Dis.
2010;42:205--9.
1. Chirletti P, Caronna R, Fanello G, Scxhiratti M, Stagnitti
F, Peparini N, et al. Pancreaticojejunostomy with applica-
tion of ﬁbrinogen/thrombin-coated collagen patch (TachoSil)
in Roux-in-Y reconstruction after pancreaticoduodenectomy. J
Gastrointest Surg. 2009;13:1396--8.
2. Toro A, Mannino M, Reale G, di Carlo I. TachoSil use in abdominal
surgery: a review. J Blood Med. 2011;2:31--6.J.  Torres-Melero  et  al.
3. Verhage RJ, Ruiz A, Verheem A, Goldschmeding R, Borel
Rinkes IH, van Hillegersberg R. Fibrin--thrombin coated sealant
increases strength of esophagogastric anastomosis in a rat
model. J Surg Res. 2012;176:e57--63.
4. Parker MC, Pohlen U, Borel IHM, Delvin T. The application of
TachoSil® for sealing colorectal anastomosis: a feasibility study.
Colorectal Dis. 2013;15:252--7.
5. De Stefano A, Capuano L, D’Ignazio A, Neri A. Use of TachoSil® in
the entero-colic anastomoses: results of an observational study.
Min Chir. 2014;69:97--105.
6. Sabino FD, Campos CF, Caetano CE, Trotte MN, Oliveira AV,
Marques RG. Effects of TachoSil® and 5-ﬂuorouracil on colonic
anastomotic healing. J Surg Res. 2014;192:375--82.
7. Sugarbaker PH. Update on the prevention of local recurrence
and peritoneal metastases in patient with colorectal cancer.
World J Gastroenterol. 2014;20:9286--91.
8. Bartlett EK, Choudhury RA, Roses RE, Fraker DL, Kelz RR,
Karakousis GC. Intraperitoneal chemotherapy at the time of
surgery is not associated with increased 30-day morbidity
and mortality following colorectal resection. Ann Surg Oncol.
2015;22:1664--72.
